ArticleStatistical methods in medical research2026
Estimating conditional survival benefit for the allocation of scarce resources.
Article in Statistical methods in medical research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Whenever treatment is scarce, the question of how to allocate resources arises. One option is to allocate based on conditional survival benefit, defined as the contrast between an individual's expected survival with and without treatment. Estimating conditional survival benefit from observational data may present the following three challenges: (i) time-dependent confounding, arising when treatments are assigned based on longitudinal health markers which are in turn affected by past assignments; (ii) multiple time scales, namely time since becoming eligible for treatment, relevant for comparability of patients, and calendar time, representing when treatment decisions are made; and (iii) multiple versions of treatment, leading to multiple counterfactual outcomes with treatment. Building on previous work where cross-sections and inverse probability of treatment weighting were combined to estimate survival benefit on the treated population, we propose a strategy to dynamically estimate conditional survival benefit for all patients awaiting scarce treatment at any time treatment becomes available, accounting for multiple versions of treatment. After delineating identifiability assumptions, we show in a simulation study that our proposed method improves the estimation of conditional survival benefit compared to simpler methods. The proposed method is then applied to liver transplant data from the Eurotransplant region.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.